Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

Rhea-AI Summary

Bluejay Diagnostics (NASDAQ: BJDX) announced a 1-for-4 reverse stock split effective at 12:01 a.m. ET on January 29, 2026. At the effective time every four issued and outstanding shares will be combined into one share, reducing outstanding common stock from approximately 2,834,133 shares to approximately 708,533. The company’s trading symbol BJDX remains unchanged and a new CUSIP 095633608 will be used post-split. Prefunded warrants will be adjusted from 1,055,000 to 263,750. No fractional shares will be issued; holders will receive a cash payment in lieu of fractional shares. Transfer agent Continental Stock Transfer & Trust Company will act as exchange agent and certificate holders will receive instructions. Equity awards and warrants will be proportionally adjusted.

The company noted it does not yet have FDA clearance for its Symphony System; its IL-6 sepsis test is designed for ~20-minute sample-to-result performance.

Positive

• Outstanding common shares consolidated from ~2,834,133 to ~708,533
• Prefunded warrants adjusted from 1,055,000 to 263,750
• New post-split CUSIP: 095633608
• Transfer agent Continental appointed as exchange agent for the split

Negative

• No fractional shares issued; holders receive cash in lieu which may alter small holdings
• The company does not yet have FDA clearance for the Symphony System, delaying U.S. commercialization

Key Figures

Reverse split ratio: 1-for-4 Outstanding shares pre-split: 2,834,133 shares Outstanding shares post-split: 708,533 shares +5 more

8 metrics

Reverse split ratio 1-for-4 Every 4 pre-split shares become 1 post-split share

Outstanding shares pre-split 2,834,133 shares Common stock before January 29, 2026 reverse split

Outstanding shares post-split 708,533 shares Common stock after 1-for-4 reverse split

Prefunded warrants pre-split 1,055,000 shares Common shares issuable on exercise before split

Prefunded warrants post-split 263,750 shares Common shares issuable on exercise after split

Par value per share $0.0001 Par value unchanged by reverse split

Effective time 12:01 a.m. ET, Jan 29, 2026 Reverse split effectiveness and start of post-split trading

Symphony IL-6 test time 20 minutes Sample-to-result time for IL-6 sepsis test candidate

Market Reality Check

Price: $0.7597 Vol: Volume 45,818 is 0.28x th...

low vol

$0.7597 Last Close

Volume Volume 45,818 is 0.28x the 20-day average of 163,284, indicating subdued trading ahead of the split. low

Technical Price 0.7903 is trading below the 200-day MA of 1.58 and 92.25% below the 52-week high of 10.20.

Peers on Argus

Only one peer, NUWE, appears in the momentum scanner, moving up by 144.19%, whil...

1 Up

Only one peer, NUWE, appears in the momentum scanner, moving up by 144.19%, while BJDX showed a -3.62% move. With no other peers in momentum and opposite directionality, the setup looks stock-specific rather than sector-driven.

Previous Stock split Reports

2 past events · Latest: Nov 13 (Negative)

Same Type Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Nov 13	Reverse stock split	Negative	-28.9%	Announced 1-for-50 reverse split, sharply reducing outstanding common shares.
Jun 17	Reverse stock split	Negative	-20.4%	Announced 1-for-8 reverse split to cut shares outstanding and adjust share price.

Pattern Detected

Prior reverse stock split announcements on Jun 17, 2024 and Nov 13, 2024 were followed by notably negative one-day reactions, suggesting this type of corporate action has historically coincided with pressure on BJDX shares.

Recent Company History

Over the past two years, Bluejay has repeatedly used reverse stock splits to manage its share structure, including a 1-for-8 split in June 2024 and a 1-for-50 split in November 2024. Both actions sharply reduced the outstanding share count and were followed by double-digit percentage declines the next day. Today’s 1-for-4 split continues this pattern of structural adjustments against a backdrop of low share price and ongoing development of the Symphony diagnostic platform.

Historical Comparison

stock split

+24.6 %

Average Historical Move

Historical Analysis

In the past year, BJDX announced 2 reverse stock splits tagged as ‘stock split,’ with an average one-day move magnitude of 24.64%, typically skewing negative.

Typical Pattern

This new <b>1-for-4</b> reverse split follows earlier <b>1-for-8</b> and <b>1-for-50</b> actions, reflecting repeated share-structure adjustments over 2024–2026.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-23

An effective shelf registration on Form S-3 filed Oct 23, 2025 covers up to 6,930,000 resale shares held by existing investors. The company itself is not selling in this registration and will not receive proceeds from resales, although it may receive cash if associated warrants are exercised.

Market Pulse Summary

This announcement details a 1-for-4 reverse stock split that reduces outstanding common shares from ...

Analysis

This announcement details a 1-for-4 reverse stock split that reduces outstanding common shares from 2,834,133 to 708,533, while adjusting prefunded warrants and equity awards proportionally. It follows earlier reverse splits in 2024 and occurs as Bluejay continues developing its Symphony IL-6 sepsis test, which targets results in about 20 minutes. Investors may track further financing steps, the existing S-3 resale registration for 6,930,000 shares, and progress toward FDA authorization for the Symphony platform.

Key Terms

reverse stock split, cusip, prefunded warrants, equity awards, +4 more

8 terms

reverse stock split financial

"approved a reverse stock split of its shares of common stock at a ratio of 1-for-4"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

cusip financial

"common stock will also commence trading with a new CUSIP number, 095633608"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

prefunded warrants financial

"reduce the number of shares of the Company’s common stock issuable upon the exercise of prefunded warrants from 1,055,000"

Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.

equity awards financial

"The shares underlying the Company’s outstanding equity awards and warrants will also be adjusted"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

transfer agent financial

"The Company has retained its transfer agent, Continental Stock Transfer & Trust Company"

A transfer agent is a financial service that keeps the official record of who owns a company's shares, handles the buying and selling of those shares on paper or electronically, and issues or cancels stock certificates. Think of it as the company’s records keeper and mailroom combined—investors rely on it to make sure dividends, shareholder mailings, ownership changes, and proxy voting are processed accurately and securely, which protects ownership rights and helps prevent errors or fraud.

near-patient testing technical

"a cost-effective, rapid, near-patient testing system for sepsis triage"

Near-patient testing means medical tests performed close to where a patient is being seen — for example in a clinic, pharmacy, ambulance, or at home — instead of being sent to a distant laboratory. For investors, it matters because these faster, simpler tests can speed diagnosis and treatment, broaden access, lower ongoing costs, and create new sales and recurring-revenue opportunities much like a compact kitchen appliance that brings restaurant capabilities into the home.

il-6 medical

"Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed"

Interleukin-6 (IL-6) is a small signaling protein the body releases as an alarm during infection, injury, or chronic inflammation; think of it as a smoke detector that calls immune cells to action. It matters to investors because IL-6 levels can serve as a biomarker for disease severity and a target for therapies—drugs that block or modulate IL-6 can change treatment outcomes, regulatory decisions, and commercial prospects in healthcare markets.

u.s. food and drug administration regulatory

"we will need to receive regulatory authorization from the U.S. Food and Drug Administration"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

AI-generated analysis. Not financial advice.

ACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-4 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on January 29, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on January 29, 2026 under the Company’s existing trading symbol, “BJDX.” At such time, the Company’s common stock will also commence trading with a new CUSIP number, 095633608.

At the effective time of the reverse stock split, every four (4) issued and outstanding shares of Bluejay common stock will be combined into one (1) share of common stock, with no change to the par value of $0.0001 per share. This will reduce the Company’s outstanding common stock from approximately 2,834,133 shares to approximately 708,533 shares (and reduce the number of shares of the Company’s common stock issuable upon the exercise of prefunded warrants from 1,055,000 to 263,750). No fractional shares of common stock will be issued as a result of the reverse stock split and instead holders of Bluejay common stock will receive a cash payment in lieu of fractional shares to which they would otherwise be entitled. The shares underlying the Company’s outstanding equity awards and warrants will also be adjusted accordingly. The reverse stock split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s common stock, except for adjustments that may result from the treatment of fractional shares.

The Company has retained its transfer agent, Continental Stock Transfer & Trust Company (“Continental”), to act as its exchange agent for the reverse stock split. Stockholders with shares held in certificate form will receive from Continental instructions regarding the exchange of their certificates. Stockholders that hold shares in book-entry form or hold their shares in brokerage accounts are not required to take any action and will see the impact of the reverse stock split reflected in their accounts, subject to brokers’ particular processes. Beneficial holders of Bluejay common stock are encouraged to contact their bank, broker, custodian or other nominee with questions regarding procedures for processing the reverse stock split.

About Bluejay Diagnostics:

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.

Forward-Looking Statements:

This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025, and in Part II, Item 1A, “Risk Factors” in the Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, filed with the SEC on May 13, 2025, August 7, 2025 and November 7, 2025, respectively. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.

Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
neil.dey@bluejaydx.com
978-631-0310

Website: www.bluejaydx.com

FAQ

What is the effective date of Bluejay Diagnostics' 1-for-4 reverse stock split (BJDX)?

The reverse stock split becomes effective at 12:01 a.m. ET on January 29, 2026, and BJDX will trade post-split that day.

How many shares will Bluejay (BJDX) have outstanding after the 1-for-4 reverse split?

Outstanding common stock will be reduced from approximately 2,834,133 shares to approximately 708,533 shares.

Will Bluejay (BJDX) change its ticker or CUSIP after the reverse split?

The trading symbol remains BJDX; the company will commence trading with a new CUSIP, 095633608, on January 29, 2026.

What happens to fractional shares from Bluejay's 1-for-4 reverse split?

No fractional shares will be issued; holders entitled to fractional shares will receive a cash payment in lieu of the fractional share.

Do Bluejay stockholders need to take action for the BJDX reverse split?

Holders in brokerage accounts or book-entry form need not take action; stockholders holding physical certificates will receive exchange instructions from Continental.

How are Bluejay's warrants and equity awards affected by the 1-for-4 split?

Outstanding equity awards and warrants will be adjusted proportionally, including prefunded warrants changing from 1,055,000 to 263,750.